Menu

ISTOCK, LJUBAPHOTO

Vaping Damages Immune Cells, Researchers Find

A small, in vitro study concludes that e-cigarette vapor harms macrophages taken from human lung tissue.

Aug 14, 2018
Catherine Offord

The vapor inhaled from e-cigarettes is toxic to immune cells in the lung known as alveolar macrophages, according to an in vitro study published yesterday (August 13) in Thorax. Using lung tissue samples from eight nonsmokers, researchers at the University of Birmingham in the UK found that, over a period of 48 hours, the vapor led to the production of reactive oxygen species, the release of inflammatory cytokines, and the inhibition of phagocytosis in the cells—calling the perceived safety of the devices into question.

“I don’t believe e-cigarettes are more harmful than ordinary cigarettes,” study coauthor David Thickett says in a statement. “But we should have a cautious scepticism that they are as safe as we are being led to believe.”

See “Swapping Cigarettes for Vaping

Previous studies of e-cigarettes’ safety have focused on the liquid used in the devices before it is vaped. This study compared unvaped and vaped e-cigarette fluid and found that the vapor itself triggered some physiological effects in lung cells that were similar to those seen in smokers and lung disease patients, such as an upregulation of proteins related to oxidative stress.

The vaped liquid is “significantly more toxic” to alveolar macrophages than the nonvaped liquid, the researchers conclude in their paper. “While further research is needed to fully understand the effects of e-cigarette exposure in humans in vivo, we caution against the widely held opinion that e-cigarettes are safe.”

Martin Dockrell of the government agency Public Health England tells BBC News that smokers should not be put off swapping their cigarettes for e-cigarettes as a way to quit smoking. “E-cigarettes are not 100% risk-free, but they are clearly much less harmful than smoking,” he says. “Any smoker considering e-cigarettes should switch completely without delay.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.